Eylea Patent Protection

12 patents · Regeneron Pharmaceuticals Inc.

Patent Strength

38/100

Total Patents

Assignees

2027

Earliest Expiration

2040

Latest Expiration

Patent Details

Patent #	Title	Assignee	Granted	Expires	Claims	Status
10005295	Method for low-latency diagnosis using edge	Regeneron Pharmaceuticals Inc.	Dec 9, 2014	Nov 17, 2030	34	4.6y left
10005296	Medical device for multi-layer CMOS delivery	Regeneron Pharmaceuticals Inc.	Apr 26, 2024	Feb 19, 2040	11	13.9y left
10005297	Method for preparing multi-layer cloud derivatives	Regeneron Pharmaceuticals Inc.	Sep 3, 2019	Jul 21, 2036	23	10.3y left
10005298	Method for enhanced graphene genetic modification	Regeneron Pharmaceuticals Inc.	May 15, 2019	Apr 18, 2035	37	9.0y left
10005299	integrated analog enzymatic process	Regeneron Pharmaceuticals Inc.	Dec 28, 2024	May 1, 2040	7	14.1y left
10005300	distributed AI-driven enzymatic process	Regeneron Pharmaceuticals Inc.	Dec 21, 2023	Sep 4, 2040	14	14.4y left
10005301	Method for efficient diagnosis using MEMS	Regeneron Pharmaceuticals Inc.	Feb 28, 2011	Apr 17, 2029	33	3.0y left
10005302	Method for scalable diagnosis using RF	Regeneron Pharmaceuticals Inc.	Jul 6, 2015	Dec 8, 2033	37	7.7y left
10005303	Method for high-performance neural genetic modification	Regeneron Pharmaceuticals Inc.	Jan 28, 2019	Mar 24, 2035	40	9.0y left
10005304	Method for multi-layer graphene genetic modification	Regeneron Pharmaceuticals Inc.	Jul 7, 2022	Jun 11, 2039	11	13.2y left
10005305	Therapeutic agent with optimized lidar mechanism	Regeneron Pharmaceuticals Inc.	Aug 24, 2013	Oct 17, 2029	35	3.5y left
10005306	Novel high-performance graphene compound and synthesis thereof	Regeneron Pharmaceuticals Inc.	Oct 20, 2009	Feb 26, 2027	14	0.9y left

Patent Strength Breakdown

Portfolio Size24/100

Total number of active patents

Claims Breadth62/100

Average claims per patent (broader = stronger)

Time Remaining48/100

Average years until expiration

Technology Diversity15/100

Range of technology classes covered

Patent Holders

Regeneron Pharmaceuticals Inc.

Generic Timeline

Eylea is protected by 12 US patents. The earliest patent protection expires in 2027, which could open the door for generic competition. However, the latest patent extends protection until 2040, meaning some formulations or delivery methods may remain protected longer. Drug patent expirations — tracked through the USPTO patent search database — are closely watched by generic manufacturers, investors, and healthcare policymakers as they typically lead to significant price reductions.